PMID- 34101576
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230413
IS  - 2148-4279 (Electronic)
IS  - 2147-9720 (Print)
IS  - 2147-9720 (Linking)
VI  - 9
IP  - 1
DP  - 2022 Jan
TI  - Juvenile spondyloartropathies.
PG  - 42-49
LID - 10.5152/eurjrheum.2021.20235 [doi]
AB  - Juvenile spondyloarthropathies (JSpA) are defined as a heterogeneous group of 
      diseases that start before the age of 16, which is associated with peripheral 
      joint (especially large joints of the lower limbs) and axial skeletal (spine and 
      sacroiliac joint) involvement, enthesitis, and human leukocyte antigen (HLA) B27 
      positivity. Juvenile spondyloarthropathies mainly cover juvenile ankylosing 
      spondylitis (JAS), psoriatic arthritis, reactive arthritis, inflammatory bowel 
      disease-associated arthritis, seronegative enthesopathy, arthropathy syndrome 
      (SEA), and enthesitis-associated arthritis. Symptoms associated with 
      spondyloarthropathies are enthesitis, inflammatory low back pain, dactylitis, 
      nail changes, psoriasis, acute anterior uveitis, and inflammatory bowel 
      disease-related symptoms. In JSpA, axial involvement is rarely seen in the early 
      stages of the disease, in contrast to adult patients with ankylosing spondylitis 
      (AS). The disease usually begins as asymmetric oligoarthritis of lower 
      extremities in children, and axial skeletal involvement can occur in the course 
      of the disease. Although the debate on the classification of juvenile 
      spondyloarthropathies continues due to its initial nonspecific findings and the 
      heterogeneity of the disease phenotype, the International League of Associations 
      Rheumatology (ILAR) classification criteria are the most commonly used pediatric 
      criteria. In that set of criteria, patients with JSpA are mainly classified under 
      enthesitis-related arthritis or psoriatic arthritis group. Since juvenile 
      spondyloarthropathies can cause severe loss of function and long-term sequelae, 
      the main goal in treatment should be suppression of inflammation as early as 
      possible and prevent sequelae.
FAU - Yildiz, Mehmet
AU  - Yildiz M
AD  - Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa School of 
      Medicine, Istanbul, Turkey.
FAU - Haslak, Fatih
AU  - Haslak F
AD  - Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa School of 
      Medicine, Istanbul, Turkey.
FAU - Adrovic, Amra
AU  - Adrovic A
AD  - Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa School of 
      Medicine, Istanbul, Turkey.
FAU - Sahin, Sezgin
AU  - Sahin S
AD  - Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa School of 
      Medicine, Istanbul, Turkey.
FAU - Barut, Kenan
AU  - Barut K
AD  - Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa School of 
      Medicine, Istanbul, Turkey.
FAU - Kasapcopur, Ozgur
AU  - Kasapcopur O
AD  - Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa School of 
      Medicine, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Eur J Rheumatol
JT  - European journal of rheumatology
JID - 101656068
SB  - IM
PMC - PMC10089147
EDAT- 2021/06/09 06:00
MHDA- 2021/06/09 06:01
PMCR- 2022/02/08
CRDT- 2021/06/08 17:28
PHST- 2021/06/09 06:00 [pubmed]
PHST- 2021/06/09 06:01 [medline]
PHST- 2021/06/08 17:28 [entrez]
PHST- 2022/02/08 00:00 [pmc-release]
AID - eurjrheum.2021.20235 [pii]
AID - ejr-9-1-42 [pii]
AID - 10.5152/eurjrheum.2021.20235 [doi]
PST - ppublish
SO  - Eur J Rheumatol. 2022 Jan;9(1):42-49. doi: 10.5152/eurjrheum.2021.20235.